Evidence map›Paper›PMID 38898954›Full record

ArticleACS pharmacology & translational science2024

Assessing the Potential of

Anna Esposito, Alice Rossi, Maria Stabile, Gabriella Pinto, Ida De Fino, Medede Melessike, Anna Tamanini, Giulio Cabrini, Giuseppe Lippi, Massimo Aureli and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Molecules (Basel, Switzerland) · 2026
    Review
  2. Frontiers in microbiology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anna EspositoDepartment of Chemical, Materials and Production Engineering, University of Naples Federico II, Naples I-80125, Italy.ORCID https://orcid.org/0000-0003-0139-8316
Alice RossiInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan I-20132, Italy.
Maria StabileDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples I-80131, Italy.
Gabriella PintoDepartment of Chemical Sciences, University of Naples Federico II, Naples I-80126, Italy.ORCID https://orcid.org/0000-0001-9169-3452
Ida De FinoInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan I-20132, Italy.
Medede MelessikeInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan I-20132, Italy.
Anna TamaniniSection of Clinical Biochemistry, Department of Engineering for Innovation Medicine, University of Verona, Verona I-37134, Italy.
Giulio CabriniCenter on Innovative Therapies for Cystic Fibrosis, Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara I-40121, Italy.
Giuseppe LippiSection of Clinical Biochemistry, Department of Engineering for Innovation Medicine, University of Verona, Verona I-37134, Italy.
Massimo AureliDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan I-20054, Italy.
Nicoletta LobertoDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan I-20054, Italy.
Mario RendaTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples I-80078, Italy.
Luis J V GaliettaTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Naples I-80078, Italy.
Angela AmoresanoDepartment of Chemical Sciences, University of Naples Federico II, Naples I-80126, Italy.
Maria Cristina DechecchiSection of Clinical Biochemistry, Department of Engineering for Innovation Medicine, University of Verona, Verona I-37134, Italy.
Eliana De GregorioDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples I-80131, Italy.
Alessandra BragonziInfections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan I-20132, Italy.
Annalisa GuaragnaDepartment of Chemical Sciences, University of Naples Federico II, Naples I-80126, Italy.ORCID https://orcid.org/0000-0001-8684-0622

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past few years, l-iminosugars have revealed attractive pharmacological properties for managing rare diseases including Cystic Fibrosis (CF). The iminosugar

Identifiers

PMID38898954
PMCPMC11184606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.